Breakthrough Therapy Designation Criteria Identify Drugs that Improve Clinical Outcomes for Patients: A Case for More Streamlined Coverage of Promising Therapies

The breakthrough therapy designation (BTD) process was created to expedite clinical development timelines for drugs intended to treat serious conditions and preliminary clinical evidence indicates the drug may demonstrate substantial improvement over existing therapies. This analysis demonstrates th...

Descripción completa

Detalles Bibliográficos
Autores principales: Collins, Grace, Stewart, Mark, McKelvey, Brittany, Stires, Hillary, Allen, Jeff
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10324637/
https://www.ncbi.nlm.nih.gov/pubmed/35616593
http://dx.doi.org/10.1158/1078-0432.CCR-22-0983

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10324637/
https://www.ncbi.nlm.nih.gov/pubmed/35616593
http://dx.doi.org/10.1158/1078-0432.CCR-22-0983

Ejemplares similares